Українська English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2022; 68(4): 20-27

Cerebrolysin administration counteracts elevated oxidative stress in blood of patients with Parkinson’s disease

O.O. Gonchar1, I.M. Karaban2, N.V. Karasevich2, L.V. Bratus1, I.M. Mankovska1

  1. Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
  2. Chebotarev Institute of Gerontology, National Academy of Medical Sciences of Ukraine, Kyiv,
DOI: https://doi.org/10.15407/fz68.04.020


Abstract

Effects of cerebrolysin (CBL) on prooxidant-antioxidant balance and oxidative stress (OS) developing in blood of patients with Parkinson’s disease (PD) were studied. Twenty patients with PD and 10 healthy persons (control) participated in this study. Clinical diagnosis of PD was established according UK Brain Bank Criteria; the grades of PD were II-III after Hoehn/Yahr. PD patients received therapy with CBL administration intravenously at dose 20 ml (61.5 mg/kg) per day along 10 days. As OS biomarkers, lipid peroxidation (from the formation of thiobarbituric acid – reactive substances, TBARS), H2O2 production, the activities of SOD, catalase, and GPx, as well as glutathione pool indexes were measured in blood plasma and erythrocytes. It was established a significant rise in TBARS in plasma and H2O2 contents in erythrocytes from patients with PD compared to control. These events were accompanied by an increase in the SOD and catalase activities in plasma and a decrease in GSH content and GPx activity in erythrocytes. CBL administration counteracts the TBARS accumulation, reduces hyperactivation of SOD and catalase in plasma compared with the CBL-untreated patients. In erythrocytes of PD patients, CBL injection caused the limitation of H2O2 production as well as promotion the GSH pool recovery through an increase in GSH level and GPx activity.

Keywords: oxidative stress; cerebrolysin; Parkinson’s disease

Full text: (PDF, in English)

References

  1. Luo Yu, Hoffer A, Hoffer B, Qi X. Mitochondria: A therapeutic target for Parkinson's disease? Int J Mol Sci. 2015;16:20704-30. CrossRef PubMed PubMedCentral
  2. Wakabayashi K, Tanji K, Odagiri S, Miki Y, Mori F, Takahashi H. The Lewy body in Parkinson's disease and related neurodegenerative disorders. Mol Neurobiol. 2013;47(2):495-508. CrossRef PubMed
  3. Gonchar OO, Maznychenko AV, Klyuchko OM, Mankovska IM, Butowska K, Borowik A, Piosik J, Sokolowska I. C60 fullerene reduces 3-nitropropionic acidinduced oxidative stress disorders and mitochondrial dysfunction in rats by modulation of p53, Bcl-2 and Nrf2 targeted proteins. Int J Mol Sci. 2021;22:5444. CrossRef PubMed PubMedCentral
  4. Hudson G. The ageing brain, mitochondria and neurodegeneration. A.K. Reeve et al. (eds.) Mitochondria dysfunction in neurodegenerative disorders. Springer Int Publ. 2016;59-80. CrossRef
  5. Gonchar OO, Klymenko OO, Drevytska TI, Bratus LV, Mankovska IM. Oxidative stress in rat heart mitochondria under a rotenone model of Parkinson' disease: a corrective effect of capicor treatment. Ukr Biochem J. 2021;93(5):21-30. CrossRef
  6. Mankovska IM, Gonchar OO, Bratus LV. The effect of Mexidol on glutathione system in rat brain under modeling of Parkinson's disease. Fiziol Zh. 2022; 65(1):13-9. [Ukrainian]. CrossRef
  7. Voutilainen MH, Arumae U, Airavaara M, Saarma M. Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson's disease. FEBS Lett. 2015;589 (24) Part A: 3739-48. CrossRef PubMed
  8. Masliah E, Díez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today. 2012;48(Suppl A):3-24.
  9. Rockenstein E, Desplats P, Ubhi K, Mante M, Florio J, Adame A, et al. Neuropeptide treatment with cerebrolysin enhances the survival of grafted neural stem cell in an a-synuclein transgenic model of Parkinson's disease. J Exp Neurosci. 2015;9(S2):131-40. CrossRef PubMed PubMedCentral
  10. Abdel-Salam OME, Mohammed NA, Youness ER, Khadrawy YA, Omara EA, Sleem AA. Cerebrolysin protects against rotenone-induced oxidative stress and neurodegeneration. J Neurorestoratol. 2014;2:47-63. CrossRef
  11. Ghaffarpasand F, Torabi S, Rasti A, Niakan M, Aghabaklou S, Pakzad F, Beheshtian SM, Tabrizi R. Effects of cerebrolysin on functional outcome of patients with traumatic brain injury: a systematic review and metaanalysis. Neuropsychiatr Dis Treatment. 2019;15:127-35. CrossRef PubMed PubMedCentral
  12. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978; 52:302-10. CrossRef
  13. Wolff SP. Ferrous ion oxidation in presence of ferric ion indicator xylenol orange for measurement of hydroperoxides. Methods Enzymol. 1994;233:182-9. CrossRef
  14. Misra HP, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem. 1972;247(10): 3170-75. CrossRef
  15. Aebi H. Catalase. In: Methods of Enzymatic Analysis, ed: Bergmeyer, H.U. Weinheim and Acad Press. 1983:227-82.
  16. Flohé L, Günzler WA. Assays of glutathione peroxidase. Methods Enzymol. 1984;105:114-21. CrossRef
  17. Sedlak J, Lindsay RH. Estimation of total, proteinbound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem. 1968;25(1):192-205. CrossRef
  18. Prigione A, Begni B, Galbussera A, Beretta S, Brighina L, Garofalo R, Andreoni S, Piolti R, Ferrarese C. Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: Negative correlation with levodopa dosage. Neurobiol Dis. 2006;23:36-43. CrossRef PubMed
  19. Younes-Mhenni S, Frih-Ayed M, Kerkeni A, Bost M, Chazot G. Peripheral blood markers of oxidative stress in Parkinson's disease. Eur Neurol. 2007;58:78-83. CrossRef PubMed
  20. Ahlskog JE, Uitti RJ, Low PA, et al: No evidence of systemic oxidant stress in Parkinson's or Alzheimer's disease. Mov Disord. 1995;10:566-73. CrossRef PubMed
  21. Buettner R. Superoxide dismutase in redox biology: The roles of superoxide and hydrogen peroxide. Anticancer Agents Med Chem. 2011;11(4):341-46. CrossRef PubMed PubMedCentral
  22. Mythri RB, Venkateshappa C, Harish G, Mahadevan A, Muthane UB, Yasha TC, Srinivas Bharath MM, Shankar SK. Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson's disease brains. Neurochem Res. 2011;36:1452-63. CrossRef PubMed
  23. Abraham S, Souandarajan CC, VivekanandhanS, Behari M. Erythrocyte antioxidant enzymes in Parkinson's disease. Ind J Med Res. 2005;121:111-5.
  24. Sudha K, Rao A, Rao S, Rao A. Free radical toxicity and antioxidants in Parkinson's disease. Neurol Ind. 2003;51: 60-2.
  25. Cokal BG, Yurtdas M, Guler SK, Gunes HN, Ucar CA, Aytac B, et al. Serum glutathione peroxidase, xanthine oxidase, and superoxide dismutase activities and malondialdehyde levels in patients with Parkinson's disease. Neurol Sci. 2016.
  26. Dickinson D, Forman H. Cellular glutathione and thiols metabolism. Biochem Pharmacol. 2002;64:1019-26. CrossRef
  27. Zeevalk G, Razmpour R, Bernard L. Glutathione and Parkinson's disease: Is this the elephant in the room. Biomed Pharmacother. 2008;62:236-49. CrossRef PubMed
  28. Nguyen SD, Hung ND, Cheon-Ho P, Ree KM, Dai-Eun S. Oxidative inactivation of lactonase activity of purified human paraoxonase 1 (PON1). Biochim Biophys Acta. 2009;1790(3):155-60. CrossRef PubMed
  29. Hochman A, Sternin H, Gorodin S, et al. Enhanced oxidative stress and altered antioxidants in brains of Bcl-2-deficient mice. J Neurochem. 1998;71(2):741-8. CrossRef PubMed
© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2025.